23 completed, 5 unknown, 4 recruiting, 4 terminated. 39 Phase 1, 14 Phase 2.
Follow Craniofacial Abnormalities: new trials by email Literature Review of Craniofacial Abnormalities trials Research Report on Craniofacial Abnormalities
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Tolerability, and Pharmacokinetics of SVG103 (Paxalisib) in Focal Cortical Dysplasia Type II (FCD-II), Tuberous Sclerosis Complex (TSC) or Hemimegalencephaly (HME) SVG103 - Focal Cortical Dysplasia, Tuberous Sclerosis Complex (TSC) | Phase 1 / Phase 2 | Recruiting | Sovargen | 12 | 2026-07-14 | 2026-08-10 |
| A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic Tumors Expressing Fibroblast Growth Factor Receptor 1 humanized monoclonal anti-FGFR1 antibody OM-RCA-01 - Renal Cell Carcinoma Metastatic, Prostate Cancer Metastatic | Phase 1 / Phase 2 | Recruiting | Kidney Cancer Research Bureau | 64 | 2025-12-02 | 2026-11-10 |
| Evaluation of Nasal Elevator Versus Grayson's Nasal Stent with D-NAM Appliance on Nasolabial Esthetics in Bilateral Cleft Lip and Palate Infants Nasal elevator with digital nasoalveolar molding in bilateral cleft lip and palate infants, Nasal stent with digital nasoalveolar molding in bilateral cleft lip and palate infants - Cleft Lip and Cleft Palate | Phase 1 | Unknown | Cairo University | 20 | 2024-11-01 | 2024-10-17 |
| Evaluating the Accuracy of Soft Tissue Prediction in Patients With Mandibular Prognathism After Orthognathic Surgery Using Handheld Scanner Versus Optical Scanner A Prospective Clinical Trial face scanning pre and post orthognathic surgery - Mandibular Prognathism, Orthognathic Surgery | Phase 1 / Phase 2 | Enrolling by invitation | Cairo University | 11 | 2024-09-24 | 2024-12-09 |
| Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations Phase 1 Part A - dose escalation TYRA-200 taken once daily by mouth in 28-day cycles, Phase 1 Part B - dose expansion TYRA-200 taken once daily by mouth in 28-day cycles - Locally Advanced Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma | Phase 1 | Active not recruiting | Tyra Biosciences, Inc | 40 | 2023-11-22 | 2026-10-14 |
| A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer Erdafitinib Intravesical Delivery System - Urinary Bladder Neoplasms, Receptors, Fibroblast Growth Factor | Phase 1 | Completed | Janssen Pharmaceutical K.K. | 5 | 2023-03-03 | 2026-11-03 |
| Melpida: Recombinant Adeno-associated Virus (Serotype 9) Encoding a Codon Optimized Human AP4M1 Transgene (hAP4M1opt) MELPIDA - Spasticity, Muscle, Microcephaly | Phase 1 / Phase 2 | Recruiting | Elpida Therapeutics SPC | 4 | 2023-02-15 | 2026-07-08 |
| BR790 in Combination With Anlotinib in Adult Subjects With Advanced Non-Small Cell Lung Cancer BR790+anlotinib - Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Unknown | Shanghai Gopherwood Biotech Co., Ltd. | 90 | 2023-02-01 | 2023-02-10 |
| Ketodex Versus Opioid Based Anaesthesia in Cleft Palate Repair Ketodex Versus Opioid Based Anaesthesia in Cleft Palate Repair Ketodex Versus Opioid Based Anaesthesia in Cleft Palate Repair Ketodex Versus Opioids in Cleft Palate Repaire Ketodex, Fentanyl - Ketodex Versus Opioids Based Anaesthesia in Cleft Palate Repair | Phase 1 | Unknown | Ain Shams University | 50 | 2022-02-01 | 2022-06-02 |
| Phase I BLASST-3 Trial Infigratinib - Bladder Transitional Cell Carcinoma, Bladder Cancer | Phase 1 | Withdrawn | Guru P. Sonpavde | 2021-12-23 | 2022-08-10 | |
| A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC ERAS-007, ERAS-601, Osimertinib - Advanced Non-squamous Non-small-cell Lung Cancer | Phase 1 | Completed | Erasca, Inc. | 24 | 2021-09-02 | 2023-07-25 |
| A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors ERAS-601, Cetuximab, Pembrolizumab - Advanced or Metastatic Solid Tumors | Phase 1 | Completed | Erasca, Inc. | 90 | 2020-12-15 | 2026-09-16 |
| Efficacy of Preconditioned Adipose-Derived Stem Cells in Fat Grafting Cultured ASCs enrichment fat grafting, Curcumin-preconditioned ASCs enrichment fat grafting, Conventional fat grafting - Romberg Disease, Craniofacial Microsomia | Phase 1 | Recruiting | University of the Punjab | 24 | 2020-11-20 | 2024-12-31 |
| A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer E7090, Fulvestrant, Exemestane - Breast Neoplasms | Phase 1 | Completed | Eisai Co., Ltd. | 51 | 2020-10-09 | 2026-07-17 |
| Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma Derazantinib, Derazantinib-paclitaxel-ramucirumab combination - Gastric Adenocarcinoma | Phase 1 / Phase 2 | Terminated | Basilea Pharmaceutica | 47 | 2020-10-06 | 2024-04-04 |
| A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China JAB-3312 - Non-small Cell Lung Cancer, Colorectal Cancer | Phase 1 | Completed | Allist Pharmaceuticals, Inc. | 17 | 2020-07-14 | 2025-05-20 |
| RLY-1971 in Subjects With Advanced or Metastatic Solid Tumors RLY-1971 - Solid Tumor, Unspecified, Adult | Phase 1 | Completed | Hoffmann-La Roche | 56 | 2020-02-04 | 2023-01-31 |
| A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors JAB-3312 - Non-small Cell Lung Cancer, Colorectal Cancer | Phase 1 | Completed | Jacobio Pharmaceuticals Co., Ltd. | 40 | 2019-09-26 | 2025-12-29 |
| Derazantinib and Atezolizumab in Patients With Urothelial Cancer Derazantinib 300 mg once daily monotherapy, Derazantinib 200 mg once daily + atezolizumab 1200 mg, Derazantinib 300 mg once daily+ atezolizumab 1200 mg - Urothelial Carcinoma | Phase 1 / Phase 2 | Completed | Basilea Pharmaceutica | 95 | 2019-08-02 | 2023-10-13 |
| Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC RMC-4630, Cobimetinib, Drug: Osimertinib - Solid Tumor | Phase 1 / Phase 2 | Completed | Revolution Medicines, Inc. | 113 | 2019-07-02 | 2023-06-26 |
Showing 20 of 39. Sign in to see all of them.
Acrocephalosyndactylia (11) · Noonan Syndrome (11) · Carcinoma, Non-Small-Cell Lung (9) · Colorectal Neoplasms (6) · Squamous Cell Carcinoma of Head and Neck (6) · Breast Neoplasms (5) · Cleft Palate (5) · DiGeorge Syndrome (5) · Neoplasms (5) · Urinary Bladder Neoplasms (5) · Esophageal Neoplasms (4) · Head and Neck Neoplasms (4) · Lung Neoplasms (4) · Thymic aplasia (4) · Cleft Lip (3)
Congenital Abnormalities (39) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (39) · Musculoskeletal Abnormalities (39) · Musculoskeletal Diseases (39) · Neoplasms (17) · Neoplasms by Site (17) · Cardiovascular Abnormalities (16) · Cardiovascular Diseases (16) · Heart Defects, Congenital (16) · Heart Diseases (16) · Bone Diseases (14) · Skin and Connective Tissue Diseases (14) · Bone Diseases, Developmental (13) · Dysostoses (13)
Thymus Extracts (2) · derazantinib (2) · infigratinib (2) · osimertinib (2) · Alpelisib (1) · Aminocaproic Acid (1) · Antilymphocyte Serum (1) · Blood Specimen Collection (1) · Botulinum Toxins, Type A (1) · Cetuximab (1) · Cyclosporine (1) · Cyclosporins (1) · Daclizumab (1) · Drug Implants (1) · Fentanyl (1)
Sumitomo Pharma Switzerland GmbH (4) · Jacobio Pharmaceuticals Co., Ltd. (3) · Basilea Pharmaceutica (2) · Cairo University (2) · Erasca, Inc. (2) · Incyte Corporation (2) · Novartis Pharmaceuticals (2) · Revolution Medicines, Inc. (2) · Aevi Genomic Medicine, LLC, a Cerecor company (1) · Ain Shams University (1) · Allist Pharmaceuticals, Inc. (1) · Eisai Co., Ltd. (1) · Elpida Therapeutics SPC (1) · Guru P. Sonpavde (1) · Hoffmann-La Roche (1)
United States (22) · Australia (5) · South Korea (5) · Spain (5) · France (4) · Italy (4) · Japan (4) · Belgium (3) · Canada (3) · Germany (3) · Brazil (2) · China (2) · Egypt (2) · Netherlands (2) · Poland (2)
M. Louise Markert, MD, PhD (3) · Revolution Medicines, Inc. (2) · Yuankai Shi, MD (2) · Azra Mehmood, PhD (1) · Baohui Han (1) · Daniela Francescato Veiga (1) · Darnell Kaigler, DDS, PhD (1) · Doug Warner (1) · Ekaterine Asatiani, MD (1) · Guru Sonpavde, MD (1) · Jaecel O Shah, MD (1)
PMID 18035553, PMID 18424759, PMID 18557726, PMID 19066739, PMID 20236866, PMID 15100156, PMID 17284531, PMID 23607606, PMID 15100681, PMID 18155964, PMID 18333898, PMID 20443823, PMID 20978268, PMID 21120277, PMID 22590644, PMID 23117614, PMID 26324363, PMID 31088831, PMID 31280362, PMID 35690720, PMID 36787089, PMID 37120522, PMID 38627238, PMID 41491634
K12HD043494 (4), R01AI047040 (4), R01AI054843 (4), R56AI047040 (2), 2017 (1), 2019 (1), 2023 (1)